Scholarlink

<p>HER2-low breast cancer (BC) representing about 40–55% of all BC has emerged as a targetable entity. However, little is known about the link between germline <i>BRCA1/2</i> mutations (<i>gBRCA1/2</i>) and HER2-low status in BC, especially in Ukrainian population. This study aims to elaborate on the rates of HER2-low status among patients with sporadic and <i>BRCA1/2</i>-associated hereditary BC in the Ukrainian population and investigate the relationship between <i>gBRCA1/2</i> and HER2 status. This was a retrospective multicenter cross-sectional study on 1412 cases of BC. HER2 status was assessed according to ASCO-CAP Guidelines. All patients underwent germline NGS testing to detect SNV and indel variants in <i>BRCA1</i> and <i>BRCA2</i> genes. Overall, <i>gBRCA1/2</i> genetic variants were found in 212 (15.0%) patients with BC. <i>gBRCA1</i> variants were associated mostly with TNBC molecular subtype, while <i>gBRCA2</i> mutations were linked to Luminal-like BC. The majority (343 of 436; 78.7%) of HER2-low BC was associated with luminal-like BC (<i>P</i> &lt; 0.001). We also found significant relationships between <i>gBRCA1/2</i> and HER2 status (<i>P</i> = 0.006). There were 837 HER2-zero (59.3%), 436 HER2-low (30.9%) and 139 HER2-positive (9.8%) BC. More than 70% of patients with <i>gBRCA1</i> were HER2-negative. Alternatively, <i>gBRCA2</i> cases possessed a higher rate of HER-low BC status (37.5%) as compared to WT (31.2%) and <i>gBRCA1</i>-associated <i>BC (</i>25.7%<i>).</i> In conclusion, <i>gBRCA1</i> and <i>gBRCA2</i> variants differed in their association with breast carcinoma molecular subtype and HER2-low status. <i>gBRCA1</i> variants were linked to the prevalence of TNBC type and HER2 zero status. In contrast, <i>gBRCA2</i> cases had a higher rate of HR + and HER-low breast cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Different association of gBRCA1 and gBRCA2 variants with HER2-low status in invasive breast cancer: findings from a Ukrainian study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月10日

查看全文
  • Sofiia Livshun,
  • Denys Kozakov,
  • Alina Kruhlykovа,
  • Olena Koshyk,
  • Nazarii Kobyliak,
  • Oleksii Seleznov,
  • Alina Matvieieva,
  • Yaroslav Shparyk,
  • Nataliia Volodko,
  • Victor Zavizion,
  • Anna Khmel,
  • Kateryna Kharchenko,
  • Natalya Otchenash,
  • Alina Andriiv,
  • Oksana Sulaieva

摘要

HER2-low breast cancer (BC) representing about 40–55% of all BC has emerged as a targetable entity. However, little is known about the link between germline BRCA1/2 mutations (gBRCA1/2) and HER2-low status in BC, especially in Ukrainian population. This study aims to elaborate on the rates of HER2-low status among patients with sporadic and BRCA1/2-associated hereditary BC in the Ukrainian population and investigate the relationship between gBRCA1/2 and HER2 status. This was a retrospective multicenter cross-sectional study on 1412 cases of BC. HER2 status was assessed according to ASCO-CAP Guidelines. All patients underwent germline NGS testing to detect SNV and indel variants in BRCA1 and BRCA2 genes. Overall, gBRCA1/2 genetic variants were found in 212 (15.0%) patients with BC. gBRCA1 variants were associated mostly with TNBC molecular subtype, while gBRCA2 mutations were linked to Luminal-like BC. The majority (343 of 436; 78.7%) of HER2-low BC was associated with luminal-like BC (P < 0.001). We also found significant relationships between gBRCA1/2 and HER2 status (P = 0.006). There were 837 HER2-zero (59.3%), 436 HER2-low (30.9%) and 139 HER2-positive (9.8%) BC. More than 70% of patients with gBRCA1 were HER2-negative. Alternatively, gBRCA2 cases possessed a higher rate of HER-low BC status (37.5%) as compared to WT (31.2%) and gBRCA1-associated BC (25.7%). In conclusion, gBRCA1 and gBRCA2 variants differed in their association with breast carcinoma molecular subtype and HER2-low status. gBRCA1 variants were linked to the prevalence of TNBC type and HER2 zero status. In contrast, gBRCA2 cases had a higher rate of HR + and HER-low breast cancer.